Lymphoma, T-Cell, Cutaneous

• 

  Subject Areas on Research

  • A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. 
  • Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. 
  • Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. 
  • Central nervous system involvement by cutaneous T cell lymphoma. 
  • Clinical and histopathologic overlap between subcutaneous panniculitis-like T-cell lymphoma with systemic features and small cell CD8+ ALK+ systemic anaplastic large cell lymphoma with cutaneous involvement. 
  • Correlations of unique clinical, immunotypic, and histologic findings in cutaneous gamma/delta T-cell lymphoma. 
  • Cutaneous Lymphoma. 
  • Cutaneous tumor in a child. Cutaneous T-cell lymphoma (CTCL). 
  • Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. 
  • Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 
  • Effects of neuroimmune axis modulation by aprepitant on antipruritic and global disease severity in patients with cutaneous T-cell lymphoma. 
  • Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. 
  • Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. 
  • Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma. 
  • Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. 
  • Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. 
  • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. 
  • Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. 
  • Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. 
  • Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. 
  • QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. 
  • Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). 
  • Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. 
  • TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). 
  • The United States Cutaneous Lymphoma Consortium (USCLC). 
  • The role for interleukin-12 therapy of cutaneous T cell lymphoma. 
  • Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. 
• 

  Keywords of People

  • Stefanovic, Alexandra, Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy